...
首页> 外文期刊>Transfusion medicine >Treatment of severe neutropenic sepsis with granulocyte transfusion in the current era--experience from an adult haematology unit in Singapore.
【24h】

Treatment of severe neutropenic sepsis with granulocyte transfusion in the current era--experience from an adult haematology unit in Singapore.

机译:在当今时代,通过粒细胞输注治疗严重的中性粒细胞减少性脓毒症-来自新加坡成人血液学部门的经验。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVES: Granulocyte transfusion's (GT) efficacy among adult severe neutropenic sepsis (SNS) patients remains uncertain. We assessed GT's efficacy and its determinants among SNS patients in an adult haematology unit. The feasibility and safety of granulocyte donation (GD) and determinants of granulocyte yield were also evaluated. METHODS: Retrospective analysis of granulocyte donors and recipients from March 2008 to October 2009. RESULTS: Donors: Sixty GDs with a median WBC yield (WBCY) of 65.49 (31.30-131.72) x 10(9) were collected from 48 donors (9 repeat donors) using hydroxyethyl starch and intermittent flow centrifugation aphaeresis after receiving 8 mg dexamethasone and 300 mcg granulocyte colony-stimulating factor, with no serious adverse reactions (SAR). Six donations were urgently collected <3 h after pre-medication, the median WBCY of which was not significantly different from donations collected >12 h after pre-medication [59.18 (45.68-62.90) x 10(9) vs 67.45 (31.30-131.72) x 10(9) , P = 0.140]. Only pre-GD absolute neutrophil count (ANC) correlated with WBCY. Patients: Fifteen patients (12 acute leukaemias, 1 severe AA, 1 myelodysplastic syndrome and 1 lymphoma) received median 3 (2-9) ABO/RhD-matched GTs over 2-24 (median 7) days at 3-61 (median 28) days from severe neutropenia (SN) onset without SAR. They received intensive chemotherapies (N = 9), allogeneic transplant (N = 3), autologous stem cell rescue (N = 1) or immunosuppressants (N = 2). Fourteen had bacterial (N = 1) infections, fungal (N = 3) infections or both (N = 10) and one had severe viral pneumonitis; 63.6 and 30.8% of bacterial and fungal infections responded, respectively. Median ANC increase (ANC(increase) ) was 1.26 (0-9.25) x 10(9) at 5-20 (median 11) h post-GT. On multivariate analysis, each patient's median ANC(increase) only significantly correlated positively with median WBC dose/kg (P = 0.013). Five (33.3%) patients survived to discharge; the rest had infection-related mortality (IRM). IRM was significantly associated with inotropic requirement (P = 0.004), ventilatory requirement (P = 0.017) and persistent SN (P = 0.007). CONCLUSION: GD is safe and feasible with good WBCY obtainable using our protocol. The effect of shortening pre-medication interval on WBCY which may prevent delay in initiating GT is worth evaluating. GT most likely benefits SNS patients with prospects of neutrophil recovery before haemodynamic deterioration. Large randomised trials investigating the role and timing of GT among such patients are required.
机译:目的:成人严重中性粒细胞减少症(SNS)患者的粒细胞输注(GT)疗效尚不确定。我们评估了成人血液学部门中SNS患者中GT的功效及其决定因素。还评估了粒细胞捐赠(GD)的可行性和安全性以及粒细胞产量的决定因素。方法:回顾性分析2008年3月至2009年10月的粒细胞供体和受体。结果:供体:从48个供体中收集了60粒GDs,白细胞平均中位数(WBCY)为65.49(31.30-131.72)x 10(9)。捐献者)在接受8 mg地塞米松和300 mcg粒细胞集落刺激因子后,采用羟乙基淀粉和间歇流离心穿刺术,无严重不良反应(SAR)。服药后3 h紧急收集了六笔捐赠,其WBCY中位数与服药后12 h的WBCY中位数无显着差异[59.18(45.68-62.90)x 10(9)vs 67.45(31.30-131.72) )x 10(9),P = 0.140]。只有GD前中性粒细胞绝对计数(ANC)与WBCY相关。患者:15例患者(12例急性白血病,1例严重AA,1例骨髓增生异常综合征和1例淋巴瘤)在3到2天(中位数为7)的3至61天(中位数为28)接受了中位3(2-9)ABO / RhD匹配的GTs严重中性粒细胞减少症(SN)发作后无SAR的天数。他们接受了强力化学疗法(N = 9),同种异体移植(N = 3),自体干细胞抢救(N = 1)或免疫抑制剂(N = 2)。十四例发生细菌性感染(N = 1),真菌感染(N = 3)或同时感染(N = 10),其中一名感染了严重的病毒性肺炎。分别有63.6和30.8%的细菌和真菌感染有反应。 GT后5-20小时(中位数11),ANC的中位数增加量(ANC(增加))为1.26(0-9.25)x 10(9)。在多变量分析中,每位患者的中位ANC(增加)仅与中位WBC剂量/ kg呈显着正相关(P = 0.013)。五(33.3%)名患者幸免于难;其余的有感染相关的死亡率(IRM)。 IRM与正性肌力需求(P = 0.004),通气需求(P = 0.017)和持续性SN(P = 0.007)显着相关。结论:使用我们的方案可获得良好的WBCY,GD是安全可行的。缩短用药前间隔时间对WBCY的影响(可防止延迟启动GT)值得评估。 GT最有可能使SNS患者受益,并有望在血流动力学恶化之前中性粒细胞恢复。需要大型随机试验来研究GT在此类患者中的作用和时机。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号